Probiotics to increase IgA secretion in infants born by Caesarean section
View Patent ↗Use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for increasing IgA secretion in an infant delivered by cesarean section during the first four months of the life of the infant.
1. A method for increasing IgA secretion in an infant delivered by caesarean section during the first four months of the life of the infant comprising administering to the infant a composition comprising a probiotic bacteria, a protein source, and an oligosaccharide mixture, the composition is administered to the infant in a therapeutically-effective amount to promote colonization of microorganism species other than the probiotic bacteria that is administered, the composition comprises the probiotic bacteria in an amount between 10 7 and 10 12 cfu/g, the probiotic bacteria comprises a strain selected from the group consisting of Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938, Lactobacillus fermentum VRI 003 (NM02/31074), Lactobacillus paracasei CNCM I-2116, Bifidobacterium lactis CNCM I-3446 , Bifidobacterium longum ATCC BAA-999, and Bifidobacterium breve Bb-03, the protein source comprising at least 50% whey by weight of the protein source, the protein source is present in the composition in an amount of not more than 2.0 g/100 kcal of the composition, and the oligosaccharide mixture comprising galacto-oligosaccharides, N-acetylated oligosaccharides and sialylated oligosaccharides in which the N-acetylated oligosaccharides are 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharides are 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharides are 1.0 to 4.0% of the oligosaccharide mixture by weight.
2. A method for improving the mucosal immune defenses of an infant delivered by caesarean section during the first four months of the life of the infant comprising administering to the infant a composition comprising a probiotic bacteria, a protein source, and an oligosaccharide mixture, the composition is administered to the infant in a therapeutically-effective amount to promote colonization of microorganism species other than the probiotic bacteria that is administered, the composition comprises the probiotic bacteria in an amount between 10 7 and 10 12 cfu/g, the probiotic bacteria comprises a strain selected from the group consisting of Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938, Lactobacillus fermentum VRI 003 (NM02/31074), Lactobacillus paracasei CNCM I-2116, Bifidobacterium lactis CNCM I-3446, Bifidobacterium longum ATCC BAA-999, and Bifidobacterium breve Bb-03, the protein source comprising at least 50% whey by weight of the protein source, the protein source is present in the composition in an amount of not more than 2.0 g/100 kcal of the composition, and the oligosaccharide mixture comprising galacto-oligosaccharides, N-acetylated oligosaccharides and sialylated oligosaccharides in which the N-acetylated oligosaccharides are 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharides are 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharides are 1.0 to 4.0% of the oligosaccharide mixture by weight.
3. The method of claim 1 , wherein the probiotic bacteria is a strain selected from the group consisting of Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938, Lactobacillus fermentum VRI 003 (NM02/31074) and Lactobacillus paracasei CNCM I-2116.
4. The method of claim 1 , wherein the probiotic is a strain selected from the group consisting of Bifidobacterium lactis CNCM I-3446 , Bifidobacterium longum ATCC BAA-999, Bifidobacterium breve Bb-03.
5. The method of claim 1 wherein the protein source has a 30:70 casein:whey ratio.
6. The method of claim 1 wherein the composition is administered to the infant immediately after delivery and thereafter for at least 2 months.
7. The method of claim 1 , wherein the composition is administered to the infant for at least 4 months after delivery.
8. The method of claim 1 , wherein the composition is administered to the infant via a breast-feeding mother.
9. The method of claim 1 , wherein the composition is an infant formula.
10. The method of claim 2 , wherein the probiotic bacteria is a strain selected from the group consisting of Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938, Lactobacillus fermentum VRI 003 (NM02/31074) and Lactobacillus paracasei CNCM I-2116.
11. The method of claim 2 , wherein the probiotic is a strain selected from the group consisting of Bifidobacterium lactis CNCM I-3446, Bifidobacterium longum ATCC BAA-999, Bifidobacterium breve Bb-03.
12. The method of claim 2 wherein the protein source is present in an amount from 1.8 to 2.0 g/l 00 kcal of the composition.
13. The method of claim 2 wherein the composition is administered to the infant immediately after delivery and thereafter for at least 2 months.
14. The method of claim 2 , wherein the composition is administered to the infant for at least 4 months after delivery.
15. The method of claim 2 , wherein the composition is administered to the infant via a breast-feeding mother.
16. The method of claim 2 , wherein the composition is an infant formula.
17. The method of claim 1 , wherein the protein source is present in an amount from 1.8 to 2.0 g/100 kcal of the composition.
18. A method comprising administering to an infant delivered by caesarean section during the first four months of the life of the infant a composition comprising a probiotic bacteria, a protein source, and an oligosaccharide mixture, the composition is administered to the infant in a therapeutically-effective amount to promote colonization of microorganism species other than the probiotic bacteria that is administered, the protein source comprising at least 50% whey by weight of the protein source, the protein source is present in the composition in an amount of 1.8 to 2.0 g/100 kcal of the composition, wherein the probiotic bacteria is Bifidobacterium longum ATCC BAA-999.